TRT and Prostate Health: The Real Picture

The concern that TRT causes prostate cancer dominated urology for over half a century. Patients still arrive at consultations asking if testosterone therapy will give them cancer. The current evidence is far more reassuring than the old teaching suggested, but it is also more nuanced than the “TRT is totally safe” marketing you see in some corners of the industry. This post covers what the research actually shows about TRT and prostate cancer, BPH, PSA changes, and the specific situation of TRT after prostate cancer treatment.

Where the Fear Came From

In 1941, urologist Charles Huggins published a Nobel Prize-winning paper showing that surgical castration (removing testosterone) shrank metastatic prostate cancer. The clinical inference drawn by most of the medical community was intuitive but flawed: if lowering testosterone treats prostate cancer, raising testosterone must cause it. This became the dominant clinical teaching for decades and drove widespread reluctance to prescribe testosterone even to men with clear hypogonadism.

The problem with that inference: the fact that androgen deprivation treats advanced prostate cancer does not imply that normal testosterone causes it. Research over the last 20 years has shown that the relationship between testosterone and the prostate is much more complicated than the original hypothesis suggested.

The Saturation Model

The current understanding is called the saturation model, proposed most prominently by Abraham Morgentaler. The core idea: prostate tissue has androgen receptors that saturate at relatively low testosterone concentrations. Once those receptors are fully occupied, adding more testosterone does not further stimulate prostate tissue growth.

Practical implication: men with truly low testosterone benefit from restoration to normal levels without triggering disproportionate prostate activity. A man at total testosterone of 200 ng/dL and a man at 800 ng/dL have essentially the same prostate stimulation from androgens; the lower man’s androgen receptors are just as saturated by the time levels reach the normal range.

What Current Evidence Shows

The large studies and meta-analyses tell a consistent story.

TRAVERSE trial. The largest randomized trial of TRT, published in 2023, tracked prostate cancer incidence as a secondary endpoint across 5,000+ men on TRT versus placebo. No statistically significant increase in prostate cancer with TRT. See our is TRT safe post for the cardiovascular findings from the same trial.

Registry data. Long-term observational data on men on TRT (some with follow-up exceeding 10 years) consistently shows prostate cancer rates that match or are slightly below expected background rates for matched populations.

Meta-analyses. Multiple meta-analyses of randomized trials and observational studies have found no increase in prostate cancer risk with TRT in men without pre-existing prostate cancer.

The Endocrine Society Clinical Practice Guideline reflects this evidence: it does not list testosterone therapy as a prostate cancer risk factor, though it does recommend PSA monitoring as part of standard TRT follow-up.

How TRT Affects PSA

PSA (prostate-specific antigen) is a blood test that reflects prostate activity. TRT causes modest PSA elevation in most men, typically 0.3 to 1.0 ng/mL over the first year. This represents the prostate becoming more metabolically active once adequate testosterone is restored, not cancer.

Normal PSA trajectory on TRT:

The typical PSA trajectory on TRT is predictable. Baseline PSA before TRT is usually 0.5 to 2.5 ng/mL in healthy men. PSA typically rises modestly in the first 3 to 6 months as the prostate responds to restored testosterone levels, with a typical increase of 0.3 to 0.5 ng/mL. After this initial adjustment, PSA generally stabilizes at the new baseline. Steady-state PSA on TRT is generally similar to what the man had during his peak testosterone years (typically his 20s and 30s).

Red flags on PSA trajectory that warrant urology referral:

• Absolute PSA above 4.0 ng/mL at any point
• Rise of more than 1.4 ng/mL in any 12-month period after the initial bump
• Rapid acceleration of PSA rise
• PSA not stabilizing after the first year
• PSA density concerns (PSA compared to prostate volume)

TRT and BPH (Benign Prostatic Hyperplasia)

BPH is age-related enlargement of the prostate that affects many older men and causes urinary symptoms: weak stream, incomplete emptying, frequency, nocturia (waking to urinate). The concern is whether TRT makes BPH worse.

Current evidence: TRT produces small increases in prostate volume (typically 5 to 10 percent), but rarely causes meaningful worsening of urinary symptoms in men with mild-to-moderate BPH at baseline. Some men actually report improvement in urinary symptoms on TRT, possibly through effects on bladder tissue and pelvic floor function.

Men with severe BPH or significant obstructive symptoms should be evaluated by urology before starting TRT. For most men with mild BPH, TRT is reasonable with baseline and periodic urinary symptom assessment (IPSS questionnaire is standard).

TRT After Prostate Cancer Treatment

This is where the conversation becomes more complex and individualized. Twenty years ago, any history of prostate cancer was considered an absolute contraindication to TRT. Current practice is more nuanced.

The American Urological Association testosterone deficiency guideline acknowledges that TRT may be considered in carefully selected men with a history of prostate cancer, particularly those with:

• Low-risk disease at original diagnosis
• Definitive treatment (surgery or radiation) with no evidence of recurrence
• Stable or undetectable PSA for at least 2 years after treatment
• Significant hypogonadal symptoms affecting quality of life
• Close collaborative monitoring with urology

Men with active prostate cancer, high-risk disease, biochemical recurrence, or on active surveillance typically should not start TRT.

The decision is made collaboratively between TRT provider, urologist, and patient. At Tactus Health, our medical team coordinates directly with the patient’s urology team when prostate cancer history is part of the clinical picture.

Standard Prostate Monitoring on TRT

Appropriate prostate monitoring during TRT follows a predictable schedule.

Baseline before starting:

The baseline prostate workup before starting TRT covers a PSA, a digital rectal exam (DRE) if indicated by age and risk profile, and a documented family history review for prostate cancer.

3 to 6 months after starting:

The 3 to 6 month follow-up repeats PSA to establish the new post-TRT baseline and includes a clinical assessment of prostate symptoms (urinary frequency, urgency, stream changes).

Annually thereafter (ages 40+):

Annual prostate monitoring on stable TRT covers PSA, a DRE when clinically indicated, and a review of any new urinary or sexual symptoms that might prompt further evaluation.

Any concerning change:

If PSA results raise concern, the response is an immediate recheck (PSA can fluctuate transiently), and a urology referral if the recheck confirms the abnormality.

When to Pause or Stop TRT for Prostate Concerns

Not every PSA blip requires stopping treatment. Circumstances that do warrant holding TRT pending urology evaluation:

• PSA above 4.0 ng/mL
• PSA doubling time less than 6 months
• Palpable abnormality on DRE
• New significant urinary symptoms
• Hematuria (blood in urine) not explained by another cause

The decision to stop TRT is not the same as the decision to permanently discontinue. Many men pause TRT for urological workup, get reassuring results, and restart.

Specific TRT and Prostate Health Scenarios

Young Men (Under 40) With Strong Family History of Prostate Cancer

No need to avoid TRT if clinically indicated. Standard monitoring is appropriate. Baseline PSA even at younger ages is helpful for establishing a personal trajectory.

Men 50 to 70 With No Prostate History

Standard TRT with standard monitoring. The vast majority of this population tolerates TRT without prostate issues.

Men With Known BPH

Usually fine on TRT, with urinary symptom monitoring. Medications for BPH (alpha blockers, 5-alpha reductase inhibitors) can continue alongside TRT.

Men With Prostate Cancer History (Treated, in Remission)

Individualized decision with urology. Often possible, with close monitoring. Usually requires 2+ years of PSA stability after treatment.

Men on Active Surveillance for Prostate Cancer

Usually not a candidate for TRT while on surveillance. The risk-benefit shifts unfavorably.

The Prostate Summary

TRT and prostate health is a conversation that has evolved significantly. The old teaching that testosterone causes cancer is not supported by current evidence. TRT can cause modest PSA elevation and small prostate volume increases; these are not inherently harmful when properly monitored. Men with pre-existing prostate cancer require specialized evaluation, but most men starting TRT can do so with confidence that standard monitoring will catch any issues that develop. Our providers include baseline PSA in every TRT evaluation and track it routinely thereafter.

Medically Reviewed By

Dr. Ashar N., DNP, APRN, FNP-C, PMHNP-BC

Co-Founder & Medical Director at Tactus Health. Dual board-certified, with clinical focus on testosterone therapy, hormone optimization, and metabolic health. In-person care in Sugar Hill, GA, and telehealth TRT for Georgia residents.